GlassScriptPhysician profile
Perri Blake Monchik
NPI 1356191704
$8,070.20
in general payments reported to CMS, 2019-2025
26 companies · $5,710 in 2025
The $5,710 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,361 · 2025: $5,710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,003 · Consulting Fee: $2,200 · Travel and Lodging: $1,867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,002.73 |
| Consulting Fee | $2,200.00 |
| Travel and Lodging | $1,867.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo USA, INC. | $3,631.45 | 2024-2025 | Xiaflex, Aveed, Edex |
| Boston Scientific Corporation | $1,674.38 | 2024-2025 | Ams 700, General - Erectile Dysfunction |
| Coloplast Corp | $1,332.32 | 2024-2025 | |
| Antares Pharma, INC. | $368.62 | 2024-2025 | Xyosted |
| Bayer Healthcare Pharmaceuticals INC. | $161.78 | 2024-2025 | |
| Axonics, INC. | $151.65 | 2024 | Axonics |
| Merck Sharp & Dohme LLC | $77.37 | 2025 | Lynparza, Keytruda |
| Janssen Biotech, INC. | $72.68 | 2025 | Erleada |
| Urogen Pharma, INC. | $69.31 | 2025 | |
| Sumitomo Pharma America, INC. | $67.46 | 2024-2025 | Orgovyx |
| Azurity Pharmaceuticals, INC. | $61.69 | 2025 | Azmiro |
| Calyxo, INC. | $54.26 | 2024-2025 | Cvac Aspiration System |
| Bluewind Medical | $43.86 | 2025 | |
| Abbvie INC. | $34.71 | 2025 | |
| Procept Biorobotics Corporation | $27.80 | 2024 | Aquabeam System |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Progenics Pharmaceuticals, INC. | $25.57 | 2025 | |
| Immunitybio, INC. | $24.15 | 2025 | |
| Dendreon Pharmaceuticals LLC | $24.10 | 2024 | Provenge |
| Teleflex LLC | $23.95 | 2024 | Urolift |
| Myriad Genetic Laboratories, INC. | $23.64 | 2025 | Myrisk |
| Telix Pharmaceuticals | $23.21 | 2025 | Illuccix |
| Accord Healthcare, INC. | $22.38 | 2025 | |
| Verity Pharmaceuticals INC. | $20.66 | 2025 | Tlando |
| Sagent Pharmaceuticals | $18.79 | 2025 | Glydo |
| Tolmar, INC. | $18.74 | 2025 | Eligard |
| Endo Pharmaceuticals INC. | $15.67 | 2024 | Xiaflex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Perri Monchik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.